Yazar "Zoghi, Mehdi" seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)(Turkish Soc Cardiology, 2021) Ekici, Berkay; Yaman, Mehmet; Kucuk, Murathan; Dereli, Seckin; Yenercag, Mustafa; Yigit, Zerrin; Zoghi, MehdiObjective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. Results: N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi. Conclusion: The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.Öğe Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey(Turkish Soc Cardiology, 2019) Gok, Gulay; Zoghi, Mehdi; Sinan, Umit Yasar; Kilic, Salih; Tokgozoglu, Lale; Sumerkan, Mutlu Cagan; Ari, HatemObjective: Heart failure (HF) has a high prevalence and mortality rate in elderly patients; however, there are few studies that have focused on patients older than 80 years. The aim of this study is to describe and compare the age-specific demographics and clinical features of Turkish elderly patients with HF who were admitted to cardiology clinics. Methods: The Epidemiology of Cardiovascular Disease in Elderly Turkish population (ELDER-TURK) study was conducted in 73 centers in Turkey, and it recruited a total of 5694 patients aged 65 years or older. In this study, the clinical profile of the patients who were aged 80 years or older and those between 65 and 79 years with HF were described and compared based on the ejection fraction (EF)-related classification: HFrEF and HFpEF (is considered as EF: >= 50%). Results: A total of 1098 patients (male, 47.5%; mean age, 83.5 +/- 3.1 years) aged 80 years and 4596 patients (male, 50.2 %; mean age, 71.1 +/- 4.31 years) aged 65-79 years were enrolled in this study. The prevalence of HF was 39.8% for patients who were >= 80 years and 27.1% for patients 65-79 years old. For patients aged >= 80 years with HF, the prevalence rate was 67% for hypertension (HT), 25.6% for diabetes mellitus (DM), 54.3% for coronary artery disease (CAD), and 42.3% for atrial fibrilation. Female proportion was lower in the HFrEF group (p=0.019). The prevalence of HT and DM was higher in the HFpEF group (p<0.01), whereas CAD had a higher prevalence in the HFrEF group (p=0.02). Among patients aged 65-79 years, 43.9% (548) had HFpEF, and 56.1% (700) had HFrEF. In this group of patients aged 65-79 years with HFrEF, the prevalence of DM was significantly higher than in patients aged >= 80 years with HFrEF (p<0.01). Conclusion: HF is common in elderly Turkish population, and its frequency increases significantly with age. Females, diabetics, and hypertensives are more likely to have HFpEF, whereas CAD patients are more likely to have HFrEF.Öğe Marital status and outcomes in chronic heart failure: Does it make a difference of being married, widow or widower?(2021) Şentürk, Bihter; Kaya, Hakkı; Çelik, Ahmet; Bekar, Lütfü; Güngör, Hasan; Zoghi, Mehdi; Yılmaz, Mehmet BirhanOBJECTIVE: We aimed to compare the outcomes of chronic heart failure (HF) patients with reduced ejection fraction (CHFrEF) in the Turkish Research Team in HF (TREAT-HF) registry according to marital status with a specific focus on being the widowed (widow/widower) versus the married.METHODS: TREAT-HF is a network, enrolling CHFrEF with a follow up for HF-related hospitalization (HFrH) and all-cause mortality (ACM). In this cohort, the widowed patients were compared with patients who were married before and after propensity score (PS) matching analysis.RESULTS: There were 723 cHFrEF patients with a complete dataset, including reported marital status at baseline for this analysis. Out of 723 patients with HF, 37 “never-married” and “divorced” patients were excluded from the analysis. Then, out of 686 remaining patients with HF, who had at least one reported marriage in the database, widowed patients with HF (n=124) were compared with married patients (n=562). The mean follow up period was 21±12 months up to 48 months. The widowed patients had a higher risk of HFrH (p=0.047), although ACM remained similar compared to married patients (p=0.054). After PS matching, HFrH remained more frequent among the widowed compared with the married (p=0.039) although ACM yielded similar rates. Of note, it was shown that being a widower (p=0.419) was not linked to increased risk of HFrH during follow up contrary to being a widow (p=0.037) despite similar age, ejection fraction, creatinine, NYHA functional class distribution and a similar rate of life-saving medications.CONCLUSION: PS matching analysis yielded that the widowed had increased the risk for HFrH. Of note, widowers did not seem to have an increased risk for HFrH, contrary to widows.Öğe Noncompliance with Dietary Salt Restriction and Outcomes in Chronic Heart Failure: A Propensity Score Matching Analysis from TREAT-HF Registry(2021) Şentürk, Bihter; Kaya, Hakkı; Çelik, Ahmet; Bekar, Lütfü; Güngör, Hasan; Zoghi, Mehdi; Yılmaz, Mehmet BirhanAim: To compare chronic heart failure patients with reduced ejection fraction (cHFrEF) who stated to comply with salt restriction in their diets versus those who did not. Methods: Patients without salt restriction were compared to those with salt restriction regarding HF-related hospitalization (HFrH) and all-cause mortality (ACM) before and after propensity score (PS) matching analysis. Results: The study included a total of 723 patients. 136 of them stated not to comply with salt restriction, 587 of them stated to comply with salt restriction. More frequent HFrH were observed in patients without salt restriction compared to those with salt restriction (75% vs. 62.9%, p=0.007), though, ACM was similar in both groups (29.4% vs 27.6%, p=0.672). After PS matching, HFrH during follow-up remained more frequent in those without salt restriction compared to those with salt restriction (73.7% vs 59.3%, p=0.019) but ACM was not different in both groups (30.5% vs 29.7%, p=0.887). Noncompliance to dietary salt restriction was found as one of the independent predictors of HFrH. Conclusion: In cHFrEF outpatients, noncompliance to dietary salt restriction does not seem to increase the risk for ACM but it poses an increased risk for HFrH.Öğe Safety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: a NOAC-TR study(Association of Basic Medical Sciences of FBIH, 2018) Emren, Sadık Volkan; Zoghi, Mehdi; Berilgen, Rida; Özdemir, İbrahim Halil; Çelik, Oğuzhan; Çetin, Nurullah; Enhoş, Asım; Köseoğlu, Cemal; Akyüz, Abdurrahman; Doğan, Volkan; Levent, Fatih; Dereli, Yüksel; Doğan, Tolga; Başaran, Özcan; Karaca, Ilgın; Karaca, Özkan; Otlu, Yılmaz Ömür; Özmen, Çağlar; Coşar, Selvi; Sümerkan, Mutlu Çağan; Gürsul, Erdal; İnci, Sinan; Onrat, Ersel; Ergene, OktayOnce-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once-or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1:1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relation to minor and major bleeding. The mean age of patients was 71 ± 10 years, and 53% of the patients were women. The medication adherence was lower in patients receiving twice-daily NOAC doses compared to once-daily-dose group (47% versus 53%, p = 0.001), and there was no difference between the groups in terms of minor (15% versus 16%, p = 0.292) and major bleeding (3% versus 3%, p = 0.796). Independent risk factors for bleeding were non-adherence to medication (OR: 1.62, 95% CI: 1.23–2.14, p = 0.001), presence of 3 or more other diseases (OR: 10.3, 95% CI: 5.3–20.3, p < 0.001), and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score (OR: 4.84, 95% CI: 4.04–5.8, p < 0.001). In summary, the once-daily dose of NOACs was associated with increased patient adherence to medication, while it was not associated with bleeding complications. © 2018 ABMSFBIH.Öğe Secondary prevention of coronary heart disease in elderly population of turkey: A subgroup analysis of Elderturk study(Via Medica, 2019) Kılıç, Salih; Sümerkan, Mutlu Çağan; Emren, Sadık Volkan; Bekar, Lütfü; Çerşit, Sinan; Tunç, Elif; Gök, Gülay; Altuntaş, Emine; Canpolat, Uğur; Sinan, Ümit Yaşar; Özmen, Namık; Zoghi, MehdiBackground: Secondary prevention plays an important role after acute coronary event due to high risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk factors and medical treatment for secondary protection in elderly patients with known coronary heart disease (CHD). Methods: ELDERTURK is a non-interventional, multi-centered, observational study, which included total of 5694 elderly patients (> 65 years) from 50 centers in Turkey. In this study elderly patients from the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comorbidities and medication usage. Results: A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and only 13.9% of patients had a recommended ? 70 mg/dL level of low-density lipoprotein cholesterol. Antiplatelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage was limited to 27.3%. Conclusions: The ELDERTURK study shows that many patients with CHD have a high prevalence of modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving therapeutic intervention and as a consequence most were not achieving the recommended goals. © 2019 Via Medica.Öğe The real-life data of hospitalized patients with heart failure: On behalf of the journey HF-TR study investigators(Turkish Society of Cardiology, 2019) Sinan, Ümit Yaşar; Ekmekçi, Ahmet; Özbay, Benay; Akyıldız Akçay, Filiz; Bekar, Lütfü; Koza, Yavuzer; Bolat, İsmail; Kocabaş, Umut; Zoghi, MehdiObjective: Acute heart failure (AHF) is a life-threatening clinical syndrome characterized by rapid onset of heart failure (HF) symptoms and signs and requires urgent therapy. The aim of the present study was to evaluate the overall clinical characteristics, management, and in-hospital outcomes of hospitalized patients with AHF in a large sample of Turkish population. Methods: The Journey HF-TR study is a cross-sectional, multicenter, non-invasive and observational trial. Patients who were hospitalized with a diagnosis of AHF in the intensive care unit (ICU)/coronary care unit and cardiology wards between September 2015 and September 2016 were included in our study. Results: A total of 1606 (male: 57.2%, mean age: 67.8±13 years) patients who were diagnosed with AHF were enrolled in the study. Seventeen percent of the patients were admitted to the hospital with a diagnosis of new onset AHF. Hypertension (67%) and coronary artery disease (CAD) (59.6%) were the most frequent underlying diseases. Acute coronary syndrome accompanying HF (14.7%), infection (29.3%), arrhythmia (25.1%), renal dysfunction (23%), and non-compliance with medication (23.8%) were the precipitating factors. The median length of stay in the ICU was 3 days (interquartile range, IQR 1–72) and 7 days (IQR 1–72) for in-hospital journey. The guideline recommended medications were less likely used in our patient population (<73%) before admission and were similar to European and US registers at discharge. The in-hospital mortality rate was 7.6%. Hypertension and CAD were the most frequent underlying diseases in our population similar to other European surveys. Although our study population was younger than other registers, in-hospital mortality was high. Conclusion: Analyses of such real-world data will help to prepare a national database and distinctive diagnosis and treatment algorithms and to provide observing compliance with the current European Society of Cardiology guidelines for more effective management of HF. © 2018 by Turkish Society of Cardiology.Öğe The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators(2019) Sinan, Ümit Yaşar; Ekmekçi, Ahmet; Özbay, Benay; Akyıldız, Filiz Akçay; Bekar, Lütfü; Koza, Yavuzer; Zoghi, MehdiObjective: Acute heart failure (AHF) is a life-threatening clinical syndrome characterized by rapid onset of heart failure (HF) symptoms and signs and requires urgent therapy. The aim of the present study was to evaluate the overall clinical characteristics, management, and in-hospital outcomes of hospitalized patients with AHF in a large sample of Turkish population. Methods: The Journey HF-TR study is a cross-sectional, multicenter, non-invasive and observational trial. Patients who were hospitalized with a diagnosis of AHF in the intensive care unit (ICU)/coronary care unit and cardiology wards between September 2015 and September 2016 were included in our study. Results: A total of 1606 (male: 57.2%, mean age: 67.8±13 years) patients who were diagnosed with AHF were enrolled in the study. Seventeen percent of the patients were admitted to the hospital with a diagnosis of new onset AHF. Hypertension (67%) and coronary artery disease (CAD) (59.6%) were the most frequent underlying diseases. Acute coronary syndrome accompanying HF (14.7%), infection (29.3%), arrhythmia (25.1%), renal dysfunction (23%), and non-compliance with medication (23.8%) were the precipitating factors. The median length of stay in the ICU was 3 days (interquartile range, IQR 1–72) and 7 days (IQR 1–72) for in-hospital journey. The guideline recommended medications were less likely used in our patient population (<73%) before admission and were similar to European and US registers at discharge. The in-hospital mortality rate was 7.6%. Hypertension and CAD were the most frequent underlying diseases in our population similar to other European surveys. Although our study population was younger than other registers, in-hospital mortality was high. Conclusion: Analyses of such real-world data will help to prepare a national database and distinctive diagnosis and treatment algorithms and to provide observing compliance with the current European Society of Cardiology guidelines for more effective management of HF. (Anatol J Cardiol 2019; 21: 25-30)Öğe Türkiye'de kalp yetersizliğinin anlık görüntüsü: SELFIE-TR bazal karakteristik özellikleri(Türk Kardiyoloji Derneği Arşivi, 2019) Yılmaz, Mehmet Birhan; Çelik, Ahmet; Çavuşoğlu, Yüksel; Bekar, Lütfü; Onrat, Ersel; Eren, Mehmet; Kutlu, Merih; Yalta, Kenan; Temizhan, Ahmet; Kılıçaslan, Barış; Güngör, Hasan; Açıkel, Mahmut; Demir, Mesut; Akdemir, Ramazan; Zoghi, Mehdi; Tokgözoğlu, LaleAmaç: Kalp yetersizliği (KY) 21. yüzyılın önemli bir sağlık sorunudur ve ülkemizdeki sıklığı %2.9’dur. Bu hastalığın ülke profili, farklı fenotiplerin sıklığı ve özellikleri, risk faktörleri net olarak ortaya konulmamıştır. Bu çalışmada, ülkemizi temsil eden bir örnekte KY hastaları (SELFIE-TR – Snapshot Evaluation of Heart Failure Patients in Turkey) incelenmiştir. Yöntemler: Ülkemizdeki 12 NUTS-1 bölgesinden en az iki kardiyoloji uzmanının çalıştığı 23 merkez çalışmaya davet edildi. Merkezler, Ekim veya Kasım aylarından tercih ettiği bir tanesinde, tercih edilen ay içindeki 4 haftanın yine tercih edilen bir gününde, tanısı kılavuzlara uygun olarak doğrulanmış KY hastalarını ardışık olarak çalışmaya dahil ettiler. Bulgular: Tüm grubun (n=1054) yaş ortalaması 63.3±13.3 yıl idi (E/K oranı: 751/303, %71.3/%28.7). Tüm kohortta kronik KY/akut KY hasta sayıları sırasıyla 712 ve 342; düşük ejeksiyon fraksiyonlu KY (DEF-KY), sınırda ejeksiyon fraksiyonlu KY (SEF-KY) ve korunmuş ejeksiyon fraksiyonlu KY (KEF-KY) hasta sayıları sırasıyla 801 (%76), 176 (%16.7), 77 (%7.3) olarak tespit edildi. Kronik KY olan hastalar akut KY olan hastalara göre daha gençti (61.1±13.3 yıl ve 67.9±12.1 yıl, p<0.001). Tüm kohortta, KY hastalarının %46’sında hipertansiyon, %27.5’inde diyabet (DM), %12.8’inde kronik ob strüktif akciğer hastalığı ve %45.2’sinde önceden geçirilmiş miyokart enfarktüsü olduğu görüldü. DEF-KY fenotipi olan kronik KY hastalarında ACEi/ARB, beta bloker ve MRA kullanım oranları sırasıyla %74.7, %89.7 ve %60.9 olarak saptandı. Sonuç: SELFIE-TR çalışması ülkemizdeki KY hastalarının anlık fotoğrafını gösteren ilk çalışma olması sebebiyle önemli bilgiler sunmaktadır. Bu bilgiler, kılavuza uygun önleyici ve tedavi edici yaklaşımların geliştirilmesi açısından faydalı olabilir.
